Rotenone, and a combination of mitocans with demonstrated anti-cancer effects (e.g., metformin), may be effective in targeting the PINK1–Parkin pathway of mitophagy in cancer, such as acute lymphoblastic leukemia (ALL) [244]. This evidence concerns the gene PRKN and acute lymphoblastic leukemia.